Sequential Paradoxical Eczema Following Interleukin‐23, Interleukin‐17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient
The Journal of Dermatology · 2026-08 · 53 (8)
DOI: 10.1111/1346-8138.70335 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Dermatology, online erschienen am 01.06.2026. Verfasst von Soomin Park und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Seoul National University College of Medicine, and Seoul National University Hospital, Seoul, Korea. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Paradoxical eczema (PE) is an increasingly recognized adverse effect of targeted psoriasis therapies, reported with biologics targeting tumor necrosis factor (TNF), interleukin (IL)- 17, IL-12/23, and IL-23 [1]. We describe a patient with chronic plaque psoriasis who developed PE sequentially with an IL-23 inhibitor (risankizumab), an IL-17 inhibitor (secukinumab), and a tyrosine kinase 2 (TYK2) inhibitor (deucravacitinib). A 58- year-old man with a 20-year history of psoriasis had previously received acitretin, methotrexate, cyclosporine, and phototherapy with inadequate disease control (Psoriasis Area and Severity Index (PASI) 17.5; body surface area (BSA) 15%). Risankizumab was initiated according to the standard schedule. By month 4, psoriasis had improved, but new facial pruritus with scaling developed. By month 7, psoriasis was almost completely controlled (PASI 0.5, BSA 1%), whereas pruritic eruptions had spread over the trunk and extremities. After 1 year, exudative
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Seoul National University College of Medicine, and Seoul National University Hospital, Seoul, Korea.
ORCID-Profile: Soomin Park
Zitieren
APA
Park, S., & Jo, S. J. (2026). Sequential Paradoxical Eczema Following Interleukin‐23, Interleukin‐17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient. The Journal of Dermatology, 53(8). https://doi.org/10.1111/1346-8138.70335
Vancouver
Park S, Jo SJ. Sequential Paradoxical Eczema Following Interleukin‐23, Interleukin‐17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient. The Journal of Dermatology. 2026;53(8). doi:10.1111/1346-8138.70335
BibTeX
@article{Park2026,
author = {Park, Soomin and Jo, Seong-Jin},
title = {Sequential Paradoxical Eczema Following Interleukin‐23, Interleukin‐17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {8},
doi = {10.1111/1346-8138.70335}
}
EUVIMED